Crinetics Pharmaceuticals Inc (CRNX) Stock Price, Quote & News

Company Profile

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in a Phase 3 clinical trial for the treatment of acromegaly and carcinoid syndrome associated with neuroendocrine tumors. It is also developing Atumelnant,...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 450 6464

Website: www.crinetics.com

Address:

6055 Lusk Boulevard, San Diego, United States

Night_Owl_Biotech Jul. 15 at 12:39 AM

$CELC is now the latest addition to our list of 23 commercial-stage oncology focused bios with market caps north of $450MM. Congratulations to CELC No one asked but attached is a comparison of CELC's valuation as a multiple of 5 year (FY28 - 32) & 8-year (FY28 - 35) analyst consensus revenue estimates to 4 very recent peer M&A oncology & non-oncology transactions (all nearing commercial-stage like CELC yesterday). The comp is not perfect but does provide a barometer of CELC potential if analyst estimates are credible & if Gedatolisib is worth peer M&A multiples should CELC exit. This is not investment advice. We're merely sharing 1 analysis of many needed to assess potential. We will update CELC's multiples to its peer oncology focused bios shortly. $CRNX $XBI $IBB $APGE

0 · Reply

WallStWireAds Jul. 14 at 4:18 PM

$NVCT https://seekingalpha.com/pr/20582379-streetwatch-nuvectis-pharma-eyes-9_8-billion-oral-pnh-market-with-late-stage-nxp100-backed-by $TGTX $VRTX $JBIO $CRNX

0 · Reply

drpgadan59 Jul. 14 at 1:31 PM

$CRNX ready for $85

0 · Reply

AIWealthCircle Jul. 13 at 8:01 PM

This week's trading watchlist is ready. These names have shown strong momentum recently, and I'm watching closely to see whether they can continue building on it. Current watchlist: $CRNX $42 → $83.6 (+99%) $FBRX $21 → $43.9 (+109%) $TRAX $18.5 → $36.2 (+96%) $WRAP $1.45 → $2.46 (+70%) $WBX $3.40 → $5.37 (+58%) Past performance doesn't guarantee the next move. I'm more interested in how these stocks react around key levels than chasing what has already happened. Risk management always comes first. If you want to see the high-conviction stocks I'm watching, my full portfolio, and every trade I make... Head to my profile.

0 · Reply

SmartMoneyRadar Jul. 13 at 7:24 PM

These stocks have been some of the strongest performers this month. Big gains don't guarantee what's next, but strong momentum is always worth keeping on the watchlist. Recent moves: $CRNX $38 → $83.6 (+120%) $FBRX $21 → $43.9 (+109%) $TRAX $18.5 → $36.2 (+96%) $WRAP $1.45 → $2.46 (+70%) $WBX $3.40 → $5.37 (+58%) Chasing isn't my strategy. I'm more interested in finding the next quality setup before it becomes obvious. The best opportunities usually appear before everyone is talking about them. Next alert is coming soon. If you're not following with notifications on, you're likely seeing the move after it already happened.

0 · Reply

EmilyMorgan1010 Jul. 13 at 7:08 PM

$CRNX I'm happy to have made a profit on another trade.

0 · Reply

SmartMoneyRadar Jul. 12 at 7:59 PM

Finding the next big winner starts with identifying opportunities early. After analyzing this week’s market moves, these stocks stood out: Key performers: $CRNX +116% $FBRX +106% $TRAX +95% $WRAP +66% $WBX +58% The biggest moves often start when a stock is still under the radar. The goal is not chasing after the breakout, but finding strong setups before momentum attracts everyone’s attention. If you want to see the high-conviction stocks I’m watching, my full portfolio, and every trade I make… Head to my profile.

0 · Reply

AIWealthCircle Jul. 12 at 7:02 PM

Looking back on this month, these were some of the key opportunities I highlighted… The focus was always the same: finding strong setups, identifying momentum, and preparing for the next wave of opportunities. Recent moves: $CRNX $42 → $83.58 $FBRX $20 → $43.92 $TRAX $20 → $36.24 $JLHL $3.7 → $11.73 $NVVE $4.9 → $13.67 The market rewards preparation. The biggest opportunities often come from spotting potential before the crowd starts paying attention. The next signal is coming. Turn on notifications and get ready to create opportunities. Keep a close eye on the next development so you don't miss out.

0 · Reply

AIWealthCircle Jul. 11 at 7:31 PM

Top Performing Stocks of 2026 (Watchlist) 🚀 These names are standing out with strong momentum and continue to attract market attention. Current watchlist: $CRNX +139% $SKHY.X +13% $MU +20% $SNDK +15% $WDC +10% The biggest opportunities often come from identifying strong trends before they become crowded. The focus is not just on past performance, but on understanding the themes and catalysts driving future growth. Investing doesn’t have to be complicated. Just listen to the smart money. Follow for more.

0 · Reply

SmartMoneyRadar Jul. 11 at 7:17 PM

I will be watching closely next week… New opportunities may be starting to appear. These stocks are on my radar: $CRNX $38 → $83 Approximately +110% $TRAX $2 → $3.5 Approximately +70% $VRXA $1.5 → $2.4 Approximately +60% $WBX $1.5 → $2.3 Approximately +50% $AMD $590 → $630 Approximately +8% Momentum creates opportunities, but the best setups come from understanding the trend, catalysts, and risk behind each move. The goal is not to chase after the breakout, but to be prepared before the market notices. If you want to see the high-conviction stocks I’m watching, my full portfolio, and every trade I make… Head to my profile.

0 · Reply

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: TriCo Bancshares (Nasdaq – TCBK), Twin Vee PowerCats Co. (Nasdaq -VEEE), Crinetics Pharmaceuticals, Inc. (Nasdaq – CRNX), Element Solutions Inc. (NYSE – ESI)

ESI TCBK VEEE

Jul 10, 2026, 8:00 AM EDT - 5 days ago

Crinetics Pharmaceuticals Proxy statement: Proxy filing

2026-07-08T13:20:58.000Z - 7 days ago

Crinetics downgraded to Hold from Buy at Stifel

Jul 8, 2026, 3:00 AM EDT - 7 days ago

How to Ride the $2.6 Trillion Merger Boom With High-Growth Stocks

VRTX

2026-07-08T01:00:09.000Z - 7 days ago

Crinetics downgraded to In Line from Outperform at Evercore ISI

2026-07-07T20:16:07.000Z - 7 days ago

Crinetics downgraded to Hold from Buy at TD Cowen

VRTX

2026-07-07T16:40:16.000Z - 7 days ago

Crinetics downgraded to Market Perform from Outperform at Citizens

2026-07-07T16:05:42.000Z - 7 days ago

Crinetics rises 98.8%

2026-07-07T14:06:08.000Z - 8 days ago

Crinetics rises 98.8%

2026-07-07T14:05:57.000Z - 8 days ago

Crinetics downgraded to Hold from Buy at Jefferies

2026-07-07T14:00:20.000Z - 8 days ago

Wedbush sees BioCryst, Ascendis as potential next targets after Crinetics deal

ASND BCRX VRTX

Jul 7, 2026, 9:38 AM EDT - 8 days ago

Crinetics shares surge after Vertex agrees to $10B cash buyout

VRTX

2026-07-07T13:35:29.000Z - 8 days ago

Crinetics downgraded to Hold from Buy at JonesResearch

Jul 7, 2026, 9:28 AM EDT - 8 days ago

SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Crinetics Pharmaceuticals, Inc. (CRNX)

VRTX

2026-07-07T12:36:21.000Z - 8 days ago

Crinetics downgraded to Neutral from Overweight at Piper Sandler

2026-07-07T11:46:02.000Z - 8 days ago

Vertex adds ‘genuine fifth commercial pillar’ with deal, says H.C. Wainwright

VRTX

2026-07-07T11:40:19.000Z - 8 days ago

Crinetics downgraded to Neutral from Buy at H.C. Wainwright

Jul 7, 2026, 7:33 AM EDT - 8 days ago

This Biotech Stock Is Soaring 99% After Vertex Agrees to Takeover Deal

VRTX

2026-07-07T10:50:24.000Z - 8 days ago

Crinetics price target raised to $85 from $62 at Baird

VRTX

Jul 7, 2026, 6:35 AM EDT - 8 days ago

Samsung, Micron, Rivian, SpaceX, Crinetics, and More Stocks That Explain Today's Market

MU RIVN SPCX

2026-07-07T09:55:09.000Z - 8 days ago

Crinetics downgraded to Perform from Outperform at Oppenheimer

VRTX

2026-07-07T08:58:13.000Z - 8 days ago

Why Is Crinetics Stock (CRNX) Surging Nearly 100% in Pre-Market Today, 7/7/26? Analysts React

VRTX

2026-07-07T01:45:12.000Z - 8 days ago

Crinetics downgraded to Neutral from Overweight at Cantor Fitzgerald

Jul 6, 2026, 5:02 PM EDT - 8 days ago

Vertex Pharmaceuticals to Acquire Crinetics Pharmaceuticals for $10 Billion

VRTX

Jul 6, 2026, 4:10 PM EDT - 8 days ago

Vertex to buy Crinetics in $10 billion deal

VRTX

Jul 6, 2026, 4:04 PM EDT - 8 days ago

Vertex to Acquire Crinetics Pharmaceuticals

VRTX

Jul 6, 2026, 8:00 AM EDT - 9 days ago

Crinetics Pharmaceuticals Proxy statement: Proxy filing

Jul 6, 2026, 8:00 AM EDT - 9 days ago

Crinetics Pharmaceuticals Proxy statement: Proxy filing

Jun 30, 2026, 4:05 PM EDT - 14 days ago

Crinetics Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 4, 2026

Jun 18, 2026, 11:00 AM EDT - 26 days ago

Crinetics Pharmaceuticals Transcript: AGM 2026

Jun 14, 2026, 2:45 PM EDT - 4 weeks ago

Crinetics Presents Long Term Data at ENDO 2026 Confirming PALSONIFY™ (paltusotine) Provides Durable, Consistent Acromegaly Control

Jun 2, 2026, 4:05 PM EDT - 6 weeks ago

Crinetics and Leading Patient Groups Launch ‘Everyday Advocacy' Initiative to Empower People Across Endocrine Disease Communities

Jun 2, 2026, 4:55 AM EDT - 6 weeks ago

Crinetics' Paradigm-Shifting Portfolio and Pipeline on Display at ENDO 2026 with Six Presentations

May 22, 2026, 4:05 PM EDT - 7 weeks ago

Crinetics Pharmaceuticals to Participate in Jefferies Global Healthcare Conference 2026

May 7, 2026, 4:30 PM EDT - 2 months ago

Crinetics Pharmaceuticals Earnings Call Transcript: Q1 2026

May 7, 2026, 4:30 PM EDT - 2 months ago

Crinetics Pharmaceuticals Earnings release: Q1 2026

May 7, 2026, 4:30 PM EDT - 2 months ago

Crinetics Pharmaceuticals Quarterly report: Q1 2026

May 7, 2026, 4:30 PM EDT - 2 months ago

Crinetics Pharmaceuticals Slides: Q1 2026

May 7, 2026, 4:05 PM EDT - 2 months ago

Crinetics Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update

Apr 29, 2026, 8:00 AM EDT - 2 months ago

Crinetics Pharmaceuticals Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 2 months ago

Crinetics Pharmaceuticals Proxy statement: Proxy filing

Apr 27, 2026, 5:13 PM EDT - 2 months ago

Crinetics Pharmaceuticals Announces the European Commission Approval of PALSONIFY® (Paltusotine) for the Treatment of Acromegaly in Adults

Apr 8, 2026, 4:05 PM EDT - 3 months ago

Crinetics Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026

Mar 26, 2026, 4:05 PM EDT - 3 months ago

Crinetics Pharmaceuticals Announces Submission of Marketing Authorization Application in Brazil for Palsonify™ (Paltusotine) in Acromegaly

Mar 4, 2026, 1:50 PM EST - 4 months ago

Crinetics Pharmaceuticals Transcript: TD Cowen 46th Annual Health Care Conference

Mar 4, 2026, 1:50 PM EST - 4 months ago

Crinetics Pharmaceuticals Slides: TD Cowen 46th Annual Health Care Conference

Feb 26, 2026, 4:30 PM EST - 4 months ago

Crinetics Pharmaceuticals Earnings Call Transcript: Q4 2025

Feb 26, 2026, 4:30 PM EST - 4 months ago

Crinetics Pharmaceuticals Annual report: Q4 2025

Feb 26, 2026, 4:30 PM EST - 4 months ago

Crinetics Pharmaceuticals Earnings release: Q4 2025

Feb 26, 2026, 4:30 PM EST - 4 months ago

Crinetics Pharmaceuticals Slides: Q4 2025

Feb 26, 2026, 4:05 PM EST - 4 months ago

Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Feb 5, 2026, 4:05 PM EST - 5 months ago

Crinetics Pharmaceuticals to Participate in Two Upcoming Investor Conferences in March

Jan 26, 2026, 5:00 PM EST - 6 months ago

Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

Jan 22, 2026, 4:05 PM EST - 6 months ago

Crinetics Initiates Phase 2/3 Pediatric Trial Evaluating Atumelnant in Congenital Adrenal Hyperplasia (CAH)

Jan 13, 2026, 12:45 PM EST - 6 months ago

Crinetics Pharmaceuticals Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 13, 2026, 12:45 PM EST - 6 months ago

Crinetics Pharmaceuticals Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 4:05 PM EST - 6 months ago

Crinetics Pharmaceuticals Announces January 2026 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jan 6, 2026, 9:22 PM EST - 6 months ago

Crinetics Pharmaceuticals Announces Pricing of Public Offering of Common Stock

Jan 5, 2026, 4:02 PM EST - 6 months ago

Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock

Jan 5, 2026, 8:30 AM EST - 6 months ago

Crinetics Pharmaceuticals Transcript: Study Update

Jan 5, 2026, 8:30 AM EST - 6 months ago

Crinetics Pharmaceuticals Press release: Study Update

Jan 5, 2026, 8:30 AM EST - 6 months ago

Crinetics Pharmaceuticals Slides: Study Update

Jan 5, 2026, 8:00 AM EST - 6 months ago

Crinetics Announces Strong PALSONIFY Launch Execution and Positive Results for Concurrent Androstenedione Lowering and Glucocorticoid Dose Reduction in Phase 2 Trial of Atumelnant for Congenital Adrenal Hyperplasia

Jan 4, 2026, 4:00 PM EST - 6 months ago

Crinetics Pharmaceuticals to Provide PALSONIFY Business Update and Announce Topline Results from Fourth Cohort of Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia

Dec 18, 2025, 4:05 PM EST - 7 months ago

Crinetics Pharmaceuticals to Participate in The 44th Annual J.P. Morgan Healthcare Conference

Dec 11, 2025, 4:05 PM EST - 7 months ago

Crinetics Announces First Patient Dosed in Pivotal Adult Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH)

Dec 10, 2025, 4:34 PM EST - 7 months ago

Crinetics Pharmaceuticals Announces December 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dec 3, 2025, 8:00 AM EST - 8 months ago

Crinetics Announces First Patient Dosed in Phase 1/2 Trial Evaluating CRN09682 for the Treatment of Neuroendocrine Tumors and Other Somatostatin Receptor 2-Expressing Tumors

Nov 20, 2025, 4:05 PM EST - 8 months ago

Crinetics Announces First Patient Randomized in Pivotal Phase 3 CAREFNDR Trial Evaluating Paltusotine in Carcinoid Syndrome

Nov 10, 2025, 4:28 PM EST - 8 months ago

Crinetics Pharmaceuticals Announces November 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nov 6, 2025, 4:30 PM EST - 8 months ago

Crinetics Pharmaceuticals Earnings Call Transcript: Q3 2025

Nov 6, 2025, 4:30 PM EST - 8 months ago

Crinetics Pharmaceuticals Quarterly report: Q3 2025

Nov 6, 2025, 4:30 PM EST - 8 months ago

Crinetics Pharmaceuticals Earnings release: Q3 2025

Nov 6, 2025, 4:30 PM EST - 8 months ago

Crinetics Pharmaceuticals Slides: Q3 2025

Nov 6, 2025, 4:05 PM EST - 8 months ago

Crinetics Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

Oct 23, 2025, 8:00 AM EDT - 9 months ago

Crinetics to Highlight Neuroendocrine Tumor Research Progress at the 2025 North American Neuroendocrine Tumor Society Annual Meeting

Oct 10, 2025, 4:41 PM EDT - 9 months ago

Crinetics Pharmaceuticals Announces October 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Oct 6, 2025, 4:05 PM EDT - 10 months ago

Crinetics Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025

Sep 25, 2025, 6:00 PM EDT - 10 months ago

Crinetics Pharmaceuticals Transcript: FDA Announcement

Sep 25, 2025, 6:00 PM EDT - 10 months ago

Crinetics Pharmaceuticals Press release: FDA Announcement

Sep 25, 2025, 6:00 PM EDT - 10 months ago

Crinetics Pharmaceuticals Slides: FDA Announcement

Sep 25, 2025, 5:30 PM EDT - 10 months ago

Crinetics Announces FDA Approval of PALSONIFY™ (paltusotine) for the Treatment of Adults with Acromegaly

Sep 10, 2025, 4:30 PM EDT - 10 months ago

Crinetics Pharmaceuticals Announces September 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aug 21, 2025, 8:45 AM EDT - 11 months ago

Crinetics Receives FDA Orphan Drug Designation for Atumelnant in the Treatment of Congenital Adrenal Hyperplasia (CAH)

Aug 11, 2025, 4:05 PM EDT - 1 year ago

Crinetics Pharmaceuticals Announces August 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aug 7, 2025, 4:30 PM EDT - 1 year ago

Crinetics Pharmaceuticals Earnings Call Transcript: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 1 year ago

Crinetics Pharmaceuticals Quarterly report: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 1 year ago

Crinetics Pharmaceuticals Earnings release: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 1 year ago

Crinetics Pharmaceuticals Slides: Q2 2025

Aug 7, 2025, 4:05 PM EDT - 1 year ago

Crinetics Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

Jul 13, 2025, 5:45 PM EDT - 1 year ago

Crinetics to Present New Long-Term Data Demonstrating Durable Control of Once-Daily, Oral PALSONIFY™ (Paltusotine) in Acromegaly at ENDO 2025

Jul 11, 2025, 8:00 AM EDT - 1 year ago

Crinetics Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 7, 2025

Jul 10, 2025, 4:28 PM EDT - 1 year ago

Crinetics Pharmaceuticals Announces July 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 30, 2025, 4:05 PM EDT - 1 year ago

Crinetics to Showcase the Next Generation of Endocrinology Innovation at ENDO 2025 with Eight Presentations From its Deep Pipeline

Jun 26, 2025, 9:00 AM EDT - 1 year ago

Crinetics Pharmaceuticals Transcript: R&D Day 2025

Jun 26, 2025, 9:00 AM EDT - 1 year ago

Crinetics Pharmaceuticals Slides: FY 2025

Jun 16, 2025, 8:00 AM EDT - 1 year ago

Crinetics Pharmaceuticals to Host R&D Day on June 26, 2025

Night_Owl_Biotech Jul. 15 at 12:39 AM

0 · Reply

WallStWireAds Jul. 14 at 4:18 PM

$NVCT https://seekingalpha.com/pr/20582379-streetwatch-nuvectis-pharma-eyes-9_8-billion-oral-pnh-market-with-late-stage-nxp100-backed-by $TGTX $VRTX $JBIO $CRNX

0 · Reply

drpgadan59 Jul. 14 at 1:31 PM

$CRNX ready for $85

0 · Reply

AIWealthCircle Jul. 13 at 8:01 PM

0 · Reply

SmartMoneyRadar Jul. 13 at 7:24 PM

0 · Reply

EmilyMorgan1010 Jul. 13 at 7:08 PM

$CRNX I'm happy to have made a profit on another trade.

0 · Reply

SmartMoneyRadar Jul. 12 at 7:59 PM

0 · Reply

AIWealthCircle Jul. 12 at 7:02 PM

0 · Reply

AIWealthCircle Jul. 11 at 7:31 PM

0 · Reply

SmartMoneyRadar Jul. 11 at 7:17 PM

0 · Reply

azv134 Jul. 11 at 4:17 PM

$LEGN started a small position yesterday using a small portion of my $CRNX gains. About 400 shares for now and will buy more at $25.3. Let’s hope XBI keeps dropping so I can add more.

0 · Reply

SmartMoneyRadar Jul. 10 at 6:41 PM

The stocks I’m watching that could see momentum next week… These names are showing strong upside moves and increased market attention. Current watchlist: $CLRO +200% $TVRD +147% $LHAI +133% $ZCMD +133% $CRNX +120% High-growth stocks can move quickly, but volatility works both ways. The focus is always on tracking momentum, catalysts, and risk before making decisions. Next alert is coming soon. If you’re not following with notifications on, you’re likely seeing the move after it already happened.

0 · Reply

AIWealthCircle Jul. 10 at 6:32 PM

Over the next two weeks, I’m keeping a close eye on these potential momentum stocks… These names are showing strong moves and could attract more market attention. Current watchlist: $CRNX +120% $38 → $83.50 $FXHO +95% $7.80 → $15.30 $LHSW +95% $1.90 → $3.80 $DXF +85% $0.35 → $0.66 $LUCY +84% $0.76 → $1.41 High-growth opportunities often come with higher volatility. The key is tracking momentum, catalysts, and risk levels before the crowd arrives. If you want to see the high-conviction stocks I’m watching, my full portfolio, and every trade I make… Head to my profile.

0 · Reply

CDMO Jul. 10 at 3:54 PM

$ARWR bringing some $CRNX gains here, Q3 will be pivotal

0 · Reply

ETAlpha Jul. 10 at 3:45 PM

Insane Options Flow Alert! $5K to $1.5M in 4 days realized?! Live midday tape update and critical open interest (OI) shifts: $AMZN: 245c 7/15 seeing heavy rotation, shifting from STO to BTC amid current volatility. $RKT: Mass institutional volume loading up the 15c 8/7 contracts. $DHT: Monthlies opening hot on a direct sympathy bet ahead of JBHT earnings next week. $CRNX: Absolute legendary trade! Someone printed $1.5M from just $5K after Monday's 100% squeeze, completely closing out yesterday! Full institutional dark pool prints and dynamic options chain risk models for all 4 tickers pinned on my profile. "A lot of great opportunities if you know where to look. The battle map has been shared in the community! Are you going to miss out again?"

0 · Reply

thesharkinthedark Jul. 9 at 7:09 PM

$ABVX this is going to 230$ if u like it or not Everything that could be bearish, is now the past 1. The offering was OVERSUBSCRIBED 4-5 times 2. Cancer cases were Nonesense 3. Company has a massive pipeline and if they run by themselves what they currently have is already worth around 165-170$ 4. In an article, they have confirmed that they are in talks with a few few big pharmas Don’t miss it. Just chill. Let them work. $XBI $ABVX $QQQ $CRNX

0 · Reply

Whiskeyunderthebed Jul. 9 at 4:02 PM

$VRTX I guess the street and shareholders didn't like the BO on $CRNX

0 · Reply

Abreeze25 Jul. 9 at 1:51 PM

$CRNX stuck in a rut apparently

1 · Reply

roscoe44 Jul. 8 at 7:21 PM

$CRNX Going to sit on my hands and wait to deploy profits from this. Nothing looks cheap. Maybe after q2 results something in watchlist will get beaten up.

0 · Reply

CH_Expat Jul. 8 at 6:33 PM

$DERM , $DBVT and $NRIX are the only serious candidates to bring some of my $CRNX profits to right now, but not for the current valuations. None of the names really thrill me. If the imevitable mega correction comes, I might also average up IDYA and MLYS

2 · Reply

svertical1 Jul. 8 at 2:00 PM

$CRNX $VRTX $CADL No doubt VRTX has a grand strategy to bolster pipeline, but Biotech acquisitions should be run similar to how great Pro teams select players in drafts, where the best remaining player is selected over the needed player. CADL vs CRNX Massive TAM vs Near term Rev https://grok.com/share/c2hhcmQtMw_b94e2328-df03-42d1-9d12-dd6ac2a51542

0 · Reply

Innerchild Jul. 8 at 1:22 PM

$OMEX 10 min left to open and its skyrocketting, lock in! 🔒 $CRNX $OPTU $SKIN

0 · Reply

Market Cap	8.82B
Revenue (ttm)	7.70M
Net Income (ttm)	-465.32M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-6,043.12%
Debt to Equity Ratio	0.00

Volume	5,086,300
Avg Vol	3,772,940
Day's Range	N/A - N/A
Shares Out	105.44M
Stochastic %K	100%
Beta	0.23
Analysts	Sell
Price Target	$81.64